The latest cancer drugs news
Browsing: Cancer Drug News
FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer
On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk, a Trop-2-directed antibody…
European Commission expands dostarlimab plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer
GSK plc announced today that the European Commission has approved dostarlimab in combination with chemotherapy…
European Commission approves lazertinib in combination with amivantamab for the first-line treatment of patients with EGFR-mutated advanced NSCLC
Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC)…
ICR welcomes NICE recommendation of olaparib for advanced breast cancer
The Institute of Cancer Research, London, UK, strongly welcomes the decision by NICE to recommend…
New drug hope for prostate cancer patients
Prostate cancer that has become resistant to hormone therapy could be treated using a new…
Generic platinum chemotherapy shortages did not increase deaths
During a shortage of the generic platinum chemotherapy drugs cisplatin and carboplatin that began in…
European Commission approves tislelizumab for first-line treatment of advanced/metastatic oesophageal squamous cell carcinoma and gastric or gastroesophageal junction cancer
European Commission has approved tislelizumab in combination with chemotherapy for the first-line treatment of oesophageal squamous…
High-tech tracking technology streamlines drug discovery
New drug discovery is a critical step for improving patients’ lives. First, researchers must identify…
FDA grants accelerated approval to asciminib for newly diagnosed chronic myeloid leukaemia
On October 29, 2024, the Food and Drug Administration granted accelerated approval to asciminib (Scemblix,…
FDA approves zolbetuximab-clzb with chemotherapy for gastric or gastroesophageal junction adenocarcinoma
Tthe Food and Drug Administration have approved zolbetuximab-clzb, a claudin 18.2 (CLDN18.2)-directed cytolytic antibody, with…